rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Nkarta, Inc.

NKTX · Nasdaq

Health CareBiotechnologyNot moving yet

NKTX stood above a rising 150-day average in 33 of the last 52 weekly readings, and has been out of that trend for the last 3 weeks. It is 32.0% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 3
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$141K
Officials’ trades on record
0
Institutions holding
132 (+12)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 33 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$126K$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months3
Buyers · sellers0 · 2
WhoDidSharesTraded
Paul J. HastingsChief Executive Officersold1,776at $2.7118 Jun 2026filed 22 Jun 2026
Nadir MahmoodPresidentsold5,649at $2.0715 Jan 2026filed 20 Jan 2026
Paul J. HastingsChief Executive Officersold26,046at $2.0715 Jan 2026filed 20 Jan 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders132+12 on the quarter
New · exited26 · 15
Reported value$162.7M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
RA CAPITAL MANAGEMENT, L.P.unchanged · filed 14 Aug 202610,805,129$30.6M00.0%
BlackRock, Inc.added · filed 7 Aug 20266,300,212$17.8M+1,791,739+39.7%
NEA Management Company, LLCunchanged · filed 14 Aug 20263,568,781$10.1M00.0%
SAMSARA BIOCAPITAL, LLCunchanged · filed 14 Aug 20263,507,666$9.9M00.0%
SR One Capital Management, LPunchanged · filed 12 Aug 20263,333,333$9.4M00.0%
GSK plcunchanged · filed 13 Aug 20263,150,732$8.9M00.0%
Monaco Asset Management SAMreduced · filed 7 Aug 20262,373,400$6.7M-148,532−5.9%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20262,226,415$6.3M+214,994+10.7%
CITADEL ADVISORS LLCadded · filed 14 Aug 20262,174,745$6.2M+390,751+21.9%
TWO SIGMA INVESTMENTS, LPreduced · filed 14 Aug 20261,873,293$5.3M-174,083−8.5%
31 Mar 2023 – 30 Jun 2026
76103130Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Paul J. Hastings Company insiderChief Executive Officer · last 18 Jun 20260 · 14
Ali Behbahani Company insiderDirector · last 10 Jun 20260 · 0
Angela Thedinga Company insiderDirector · last 10 Jun 20260 · 0
George Vratsanos Company insiderDirector · last 10 Jun 20260 · 0
Leone D. Patterson Company insiderDirector · last 10 Jun 20260 · 0
Michael Dybbs Company insiderDirector · last 10 Jun 20260 · 0
RA CAPITAL MANAGEMENT, L.P. Company insiderDirector, 10% owner · last 10 Jun 20261 · 0
Rajeev M. Shah Company insiderDirector, 10% owner · last 10 Jun 20262 · 0
Simeon George Company insiderDirector · last 10 Jun 20262 · 0
Zachary Scheiner Company insiderDirector · last 10 Jun 20260 · 0
Nadir Mahmood Company insiderPresident · last 15 Jan 20260 · 10
Shawn Marshall Rose Company insiderOfficer · last 6 Jan 20260 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-31.9%
Share count trendFY 2025 · to 18 Mar 20260.3%
Cash and equivalentsFY 2025 · to 31 Dec 2025$39.6M
Free cash flowFY 2025 · to 31 Dec 2025−$89.9M

Analyst forecasts

No analyst forecasts yet.